Baxter International (NYSE:BAX) Price Target Lowered to $31.00 at Evercore ISI

Baxter International (NYSE:BAX) had its target price reduced by Evercore ISI from $33.00 to $31.00 in a report published on Tuesday morning,Benzinga reports. Evercore ISI currently has an outperform rating on the medical instruments supplier’s stock.

A number of other equities analysts have also recently weighed in on BAX. UBS Group decreased their price objective on Baxter International from $35.00 to $24.00 and set a “neutral” rating on the stock in a report on Monday, August 4th. Citigroup decreased their price objective on Baxter International from $34.00 to $32.00 and set a “neutral” rating on the stock in a report on Wednesday, July 9th. Wall Street Zen cut Baxter International from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Stifel Nicolaus reissued a “hold” rating and set a $25.00 price objective (down from $36.00) on shares of Baxter International in a report on Monday, August 4th. Finally, Barclays decreased their price objective on Baxter International from $41.00 to $36.00 and set an “overweight” rating on the stock in a report on Monday, August 4th. Three equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Baxter International has a consensus rating of “Hold” and a consensus price target of $28.89.

Baxter International Stock Performance

Shares of BAX opened at $22.90 on Tuesday. The company has a market cap of $11.76 billion, a PE ratio of -76.32, a price-to-earnings-growth ratio of 0.75 and a beta of 0.58. The company has a current ratio of 2.30, a quick ratio of 1.49 and a debt-to-equity ratio of 1.30. The stock has a 50-day moving average price of $23.66 and a 200-day moving average price of $27.96. Baxter International has a 12-month low of $21.33 and a 12-month high of $38.28.

Baxter International (NYSE:BAX) last issued its quarterly earnings results on Thursday, July 31st. The medical instruments supplier reported $0.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.01). The business had revenue of $2.81 billion for the quarter, compared to the consensus estimate of $2.82 billion. Baxter International had a negative net margin of 1.42% and a positive return on equity of 16.96%. The business’s revenue was up 4.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.68 EPS. Baxter International has set its Q3 2025 guidance at 0.580-0.620 EPS. FY 2025 guidance at 2.420-2.520 EPS. As a group, equities analysts forecast that Baxter International will post 2.48 earnings per share for the current fiscal year.

Baxter International Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, October 1st. Stockholders of record on Friday, August 29th were given a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date was Friday, August 29th. Baxter International’s dividend payout ratio (DPR) is currently -226.67%.

Institutional Investors Weigh In On Baxter International

Large investors have recently made changes to their positions in the business. Zions Bancorporation National Association UT bought a new stake in shares of Baxter International in the 1st quarter worth approximately $27,000. CoreFirst Bank & Trust bought a new stake in shares of Baxter International in the 2nd quarter worth approximately $27,000. Rossby Financial LCC bought a new stake in shares of Baxter International in the 1st quarter worth approximately $29,000. Creative Financial Designs Inc. ADV grew its position in shares of Baxter International by 169.6% in the 2nd quarter. Creative Financial Designs Inc. ADV now owns 984 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 619 shares during the last quarter. Finally, MTM Investment Management LLC bought a new stake in shares of Baxter International in the 2nd quarter worth approximately $30,000. 90.19% of the stock is currently owned by institutional investors.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.